Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (881-890 of 962) with videos related to

Pageof 97
Sort By:
Lancet (London, England)|March 23, 2017
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trialE Magnus Ohman, Matthew T Roe, P Gabriel Steg, et al.
American Heart Journal|August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and designSneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
Journal of the American College of Cardiology|November 2, 2019
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary StentingAnna Franzone, Eugène McFadden, Sergio Leonardi, et al.
European Heart Journal|July 12, 2018
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)Marco Valgimigli, Hector M Garcia-Garcia, Bernard Vrijens, et al.
Circulation. Cardiovascular Quality and Outcomes|February 4, 2021
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSYSergio Leonardi, Mattia Branca, Anna Franzone, et al.
International Journal of Cardiology|March 9, 2019
Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS studyPly Chichareon, Rodrigo Modolo, David van Klaveren, et al.
European Journal of Preventive Cardiology|February 9, 2026
Improving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk scoreJoris Holtrop, Mari N Gynnild, Matthew Richards, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2024
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trialUsman Baber, Davide Cao, Timothy Collier, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 16, 2025
Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trialMauro Gitto, Usman Baber, Samantha Sartori, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 18, 2019
Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trialMariusz Tomaniak, Ply Chichareon, Rodrigo Modolo, et al.
Pageof 97

Showing results (881-890 of 962) with videos related to

Sort By:
Pageof 97
Lancet (London, England)|March 23, 2017
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trialE Magnus Ohman, Matthew T Roe, P Gabriel Steg, et al.
American Heart Journal|August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and designSneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
Journal of the American College of Cardiology|November 2, 2019
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary StentingAnna Franzone, Eugène McFadden, Sergio Leonardi, et al.
European Heart Journal|July 12, 2018
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)Marco Valgimigli, Hector M Garcia-Garcia, Bernard Vrijens, et al.
Circulation. Cardiovascular Quality and Outcomes|February 4, 2021
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSYSergio Leonardi, Mattia Branca, Anna Franzone, et al.
International Journal of Cardiology|March 9, 2019
Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS studyPly Chichareon, Rodrigo Modolo, David van Klaveren, et al.
European Journal of Preventive Cardiology|February 9, 2026
Improving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk scoreJoris Holtrop, Mari N Gynnild, Matthew Richards, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2024
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trialUsman Baber, Davide Cao, Timothy Collier, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 16, 2025
Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trialMauro Gitto, Usman Baber, Samantha Sartori, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 18, 2019
Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trialMariusz Tomaniak, Ply Chichareon, Rodrigo Modolo, et al.
Pageof 97